Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort
Mark Davids1, Hilde Herrema1, Albert K Groen1
1Department of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Background & Aims:
Proton pump inhibitor (PPI) use has been associated with metabolic dysfunction associated with steatotic liver disease (MASLD) in multiple studies. While the association is confounded by various risk factors, such as BMI and age, a potential mediating factor of the microbiome has been suggested. In this study, we aimed to identify bacterial clades with the highest mediating potential and evaluate the serially mediated path through microbially derived endogenous ethanol.
Methods:
Microbiome mediation analysis of PPI use and MASLD was conducted in two cohorts. In a bariatric surgery cohort (n = 122), liver biopsy-proven steatosis grade and postprandial ethanol concentrations were used as outcomes. In the HELIUS cohort (n = 2440), a general population cohort study, mediation was performed using the Fatty Liver Index (FLI) score. The strongest associations were validated in the FINRISK cohort (n = 7066).
Results:
Several bacterial taxa, which are predominantly found in the small intestine, showed a potential role in mediating the effects of PPIs on MASLD, postprandial ethanol levels, and FLI score. The Lactobacillales order showed the strongest mediating potential across the outcomes tested in both discovery cohorts. A notable serial mediation pathway was identified, linking PPI use to MASLD via Lactobacillales abundance and postprandial plasma ethanol concentrations. The mediating role of Lactobacillales in the association between PPI use and FLI scores was confirmed in the final study cohort.
Conclusions:
Data from multiple cross-sectional cohort studies support a mediating potential of the microbiome in the association between PPI use and hepatic steatosis, independent of alcohol consumption. The effect of PPIs on MASLD appears to be mediated mainly by increased lactic acid bacteria abundance, and is potentially, in part, serially mediated by endogenous ethanol production.
Insights
Proton pump inhibitor (PPI) use may contribute to metabolic dysfunction associated with steatotic liver disease (MASLD) by altering the gut microbiome. Specifically, increased lactic acid bacteria abundance, potentially leading to higher ethanol levels, mediates this association.
Area of Science:
- Gastroenterology
- Microbiome Research
- Metabolic Disease
Background:
- Proton pump inhibitor (PPI) use is linked to metabolic dysfunction associated with steatotic liver disease (MASLD).
- The gut microbiome is a potential mediator in this association, independent of traditional risk factors like BMI and age.
Purpose of the Study:
- To identify bacterial clades with the highest mediating potential in the PPI-MASLD association.
- To evaluate the serial mediation pathway involving microbially derived endogenous ethanol.
Main Methods:
- Microbiome mediation analysis was performed in bariatric surgery, HELIUS, and FINRISK cohorts.
- Outcomes included liver biopsy-proven steatosis grade, postprandial ethanol concentrations, and Fatty Liver Index (FLI) score.
Main Results:
- The Lactobacillales order demonstrated the strongest mediating potential across tested outcomes.
- A serial mediation pathway was identified: PPI use -> Lactobacillales abundance -> postprandial ethanol -> MASLD/FLI.
Conclusions:
- The microbiome mediates the association between PPI use and hepatic steatosis.
- Increased lactic acid bacteria (Lactobacillales) abundance is a key mediator, potentially involving endogenous ethanol production.
More Related Videos
06:58Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems
Published on: August 23, 2019
08:37Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Microbial Fermentation
Microbes in the Production of Fermented Foods
Microbes in Beverage Production
Microbes in Food Production
Probiotics
